Patent application number | Description | Published |
20080200442 | Compositions and Methods for Treating, Reducing, Ameliorating, or Preventing Infections of the Ear or Upper Respiratory Tract - Compositions for treating, reducing, ameliorating, or preventing infection of an ear or upper respiratory tract comprise a fluroquinolone having Formula I, II, or III. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against certain antibiotic-resistant microbial pathogens found in such infection. | 08-21-2008 |
20080293728 | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions - A complex comprises at least an α | 11-27-2008 |
20090082337 | Compositions Comprising Quinolone and Methods for Treating or Controlling Infections - Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site. | 03-26-2009 |
20100087550 | Formulations with a Tertiary Amine Oxide - A topical pharmaceutical formulation comprising 0.5 ppm to 1000 ppm of a tertiary amine oxide of general formula I | 04-08-2010 |
20100104551 | METHOD FOR PROLONGING ACTIVITY OF AUTODEGRADABLE ENZYMES AND COMPOSITIONS THEREOF - A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment. | 04-29-2010 |
20100125077 | Polymorphs of Brimonidine Pamoate - A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system. | 05-20-2010 |
20110183946 | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma - A complex comprises at least an α | 07-28-2011 |
20110251147 | Compositions Comprising Quinolone and Methods for Treating or Controlling Infections - Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site. | 10-13-2011 |
20120015951 | Polymorphs of Brimonidine Pamoate - A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system. | 01-19-2012 |
20120196840 | Compositions and Methods for Treating, Reducing, Ameliorating, or Preventing Infections - Compositions for treating, reducing, ameliorating, or preventing infections comprise a fluoroquinolone having Formulae I-VIII and an additional anti-infective agent. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against mixed types of pathogens including certain antibiotic-resistant microbial pathogens found in such infections. | 08-02-2012 |
Patent application number | Description | Published |
20090081545 | HIGH CAPACITY AND HIGH RATE LITHIUM CELLS WITH CFx-MnO2 HYBRID CATHODE - A nonaqueous cell employing an anode such as lithium or lithium alloy, a liquid lithium salt nonaqueous electrolyte, a thermal shutdown separator and a cathode comprising a homogeneous hybrid mixture of carbon fluoride and manganese dioxide, said carbon fluoride or poly-carbon fluoride being represented by the formula (CFx) wherein 0.5≦x≦1.2 and contained in said mixture in a ratio by weight of about 5 to 99%, preferably about 5 to 50% and said manganese dioxide is heat treated electrolytic manganese dioxide represented by EMD or MnO | 03-26-2009 |
20100068609 | HYBRID CELL CONSTRUCTION FOR IMPROVED PERFORMANCE - A hybrid lithium electrochemical cell comprising a spirally wound cathode, separator and anode in a generally cylindrical structure with the packaging materials and terminal structure of a pouch cell. The cell may also contain a welded metal grid outside the pouch cell packaging material to insure a cylindrical shape. The resultant hybrid cell features improved capacity and specific energy. | 03-18-2010 |
20130236756 | LITHIUM BOBBIN CELL WITH CATHODE USING WRAPPED METAL GRID AS CURRENT COLLECTOR - Improved structure and performance are disclosed for lithium cylindrical primary and secondary bobbin cells having an improved cathode and current collector. This collector can be a metal screen, mesh or grid, and may further be treated with carbon or cathode mix components and then wrapped around the cathode and embedded into its surface. This metal grid collector reduces cell impedance, and increases discharge rate capability as well as low temperature performance. The cathode for these cells is surrounded by the anode and may also have a hole through its center to provide improved manufacturability and reduced cost for the cells. | 09-12-2013 |